Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.48 |
| ▸ | WNT3A | P56704 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.40 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011103 | 1.00 | CTNNB1 (0.48) | CTNNB1WNT3AHCRTR1HCRTR2EPHX2 | |
| SCHEMBL2012361 | 0.93 | HCRTR1 (0.46) | CTNNB1WNT3AHCRTR1HCRTR2EPHX2 | |
| SCHEMBL13138986 | 0.93 | HCRTR1 (0.46) | CTNNB1WNT3AHCRTR1HCRTR2EPHX2 | |
| SCHEMBL13138952 | 0.88 | HCRTR1 (0.51) | HCRTR1HCRTR2EPHX2KMT2AMEN1 | |
| SCHEMBL13138976 | 0.88 | HCRTR1 (0.51) | HCRTR1HCRTR2EPHX2KMT2AMEN1 | |
| SCHEMBL13138970 | 0.84 | KMT2A (0.55) | HCRTR1HCRTR2EPHX2KMT2AMEN1 | |
| SCHEMBL13138994 | 0.84 | KMT2A (0.55) | HCRTR1HCRTR2EPHX2KMT2AMEN1 | |
| SCHEMBL2011137 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2EPHX2KMT2APADI4 | |
| SCHEMBL2011138 | 0.83 | HCRTR1 (0.49) | HCRTR1HCRTR2EPHX2KMT2APADI4 | |
| SCHEMBL2015295 | 0.83 | HCRTR1 (0.46) | CTNNB1WNT3AHCRTR1HCRTR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | CTNNB1 2500/4885WNT3A 4271/4885HCRTR1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.